The large-scale phase-III clinical trials conducted with the PALOMA, MONALEESA, MONARCH, and DAWNA series have confirmed that CDK4/6 inhibitors play a pivotal role in extending progression-free survival and overall survival in HR-positive breast cancer patients [3]. The gene discussed is CDK4; the disease is breast carcinoma.